Natural Killer Cells Could Be Used to Treat Myeloma, Small Study Suggests
A new immunotherapy using natural killer cells showed promise in a small proof-of-concept Phase 1 trial of relapsed or refractory multiple myeloma patients who also…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
ASCT Benefited Younger, Older Multiple Myeloma Patients Equally, Study Finds
Multiple myeloma patients older than 65 years benefit as much as younger patients from autologous stem cell transplant (ASCT), according to a recent retrospective study.
Alkeran-based 4-drug Combo Gives Excellent Outcomes in Myeloma Patients Undergoing Transplants
A combination treatment of four drugs including the chemotherapy agent Alkeran (melphalan) gives excellent short-term outcomes in multiple myeloma patients who undergo stem cell transplants,…
Revlimid for Myeloma After Stem Cell Transplant Gets Nod from EMA Panel
The use of Revlimid (lenalidomide) as a maintenance therapy for adult patients with newly diagnosed multiple myeloma who underwent autologous stem cell transplant (ASCT)…
Combo Therapy After Stem Cell Transplant Improves Survival in Myeloma Patients, Trial Finds
Combination treatment with Velcade (bortezomib) and Thalomid (thalidomide) may significantly improve survival of multiple myeloma patients who received a stem cell transplant, according to recent…
Cellectar’s Patent for Anti-cancer Compounds Includes Potential Myeloma Therapy
Cellectar Biosciences has been granted a U.S. patent for the method of use for the compounds CLR 131 and CLR 125 in the treatment of…
